Vraylar (Cariprazine) is an atypical antipsychotic that is most frequently prescribed as a pharmacological intervention for schizophrenia and bipolar disorder. The medication functions predominantly as a: D3 and D2 receptor partial agonist, 5-HT2B receptor antagonist, and 5-HT1A partial agonist. To a less significant extent, Vraylar interacts with H1 receptors and 5-HT2A receptors as an antagonist. …
Vraylar (Cariprazine), is an atypical antipsychotic medication approved in 2015 by the FDA for the treatment of schizophrenia and bipolar disorder. Occasionally, Vraylar is also prescribed as an adjunct for treatment-resistant depression and off-label for anxiety disorders. Although Vraylar is marketed as an improvement over older atypical antipsychotic medications in terms of efficacy and tolerability, …
Vraylar (Cariprazine), also sold under the name Reagila [in European countries], is an atypical antipsychotic developed by the pharmaceutical company Allergan. In 2015, Vraylar received FDA approval for the treatment of schizophrenia and mania associated with bipolar disorder. From a pharmacodynamic perspective, Vraylar functions predominantly as a partial agonist at D3 and D2 dopamine receptors, …
Rexulti (Brexpiprazole), is an atypical antipsychotic that was jointly developed by pharmaceutical companies Otsuka and Lundbeck. In 2015, the FDA approved Rexulti for the treatment of schizophrenia and major depressive disorder (as an adjunct). Rexulti functions as a “serotonin-dopamine activity modulator” (SDAM) and is intended to be a superior successor to the antipsychotic Abilify (Aripiprazole) …
Rexulti (Brexpiprazole), is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia and major depressive disorder (as an adjunct). The drug was engineered via collaboration between pharmaceutical companies Otsuka and Lundbeck and is considered the successor to Abilify (aripiprazole), a formerly top-selling antipsychotic medication with an expired patent. Although Rexulti is marketed …
Seroquel (Quetiapine) is an atypical antipsychotic engineered in the early 1990s by the pharmaceutical company AstraZeneca. It was first approved by the FDA in 1997 for the treatment of schizophrenia, and was sequentially approved by the FDA in 2004 for the management of bipolar mania. Seroquel would also receive subsequent FDA approval in 2009 as …
Seroquel (Quetiapine) is a medication that was developed by AstraZeneca from 1992 through 1996. It received FDA approval in 1997 for the treatment of schizophrenia, and has since received approval to treat both acute mania and depressive phases of bipolar disorder. The drug is classified as an atypical, second-generation antipsychotic and exerts pharmacological effects via …